Glycated Albumin Market Size, Share, Growth, And Industry Analysis, By Type (Glycated, Albumin (Human), and Glycated Albumin (Animal)), By Application (Hospitals and Clinics & Laboratories), Regional Insights, and Forecast To 2035

•   
•   
  

  Request a Free sample to learn more about this report

    

GLYCATED ALBUMIN MARKET OVERVIEW

global glycated albumin market size was USD 0.47 billion in 2023 and market is projected to touch USD 0.8 billion by 2032 at CAGR 6.11% during the forecast period. North America leads with 38% market share; Europe holds 30%; Asia-Pacific 25%; Rest of World 7%.

Glycated albumin, also known as glycosylated albumin or fructosamine, is a biomarker used in the monitoring of blood glucose levels over a shorter time period than hemoglobin A1c (HbA1c). While HbA1c provides an average of blood glucose levels over the past 2-3 months, glycated albumin reflects changes in blood glucose levels over a shorter time frame, typically the preceding 2-4 weeks. Glycated albumin is a useful tool for healthcare professionals in managing and accessing glycemic control in individuals with diabetes, particularly when they need to monitor shorter-term changes in blood sugar levels. It provides additional insights into glucose management alongside HbA1c measurements.

The glycated albumin market refers to the segment of the healthcare industry that deals with the production, distribution, and marketing of products and services related to glycated albumin testing. This market primarily serves healthcare providers, clinical laboratories, and individuals with diabetes or other conditions where monitoring short-term blood glucose control is essential.

KEY FINDINGS

COVID-19 IMPACT

Market Faced a Fall in Demand Due to Disruption of Healthcare Services During the Pandemic

The global COVID-19 pandemic has been unprecedented and staggering, with the Glycated Albumin market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market's growth and demand returning to pre-pandemic levels once the pandemic is over.

There was no single sector unaffected by COVID-19. In the early stages of the pandemic, many healthcare resources were diverted to COVID-19 testing and treatment. This disruption affected routine healthcare services, including diagnostic testing like glycated albumin measurements.

LATEST TRENDS

Continuous Glucose Monitoring (CGM) Integration to Improve the Efficiency in the Market  

The Glycated Albumin market is as dynamic as any other market. The integration of glycated albumin testing with continuous glucose monitoring systems is a trend that can provide a more comprehensive view of a patient's glycemic control over time. This trend aligns with the broader shift towards real-time data in healthcare.

• According to the American Diabetes Association, over 48% of clinical laboratories in the U.S. now use glycated albumin testing for intermediate-term glycemic control.

•  The U.S. FDA database shows that 35% of newly approved point-of-care diagnostic devices for diabetes incorporate glycated albumin as a biomarker in 2024.

  

Request a Free sample to learn more about this report

  

GLYCATED ALBUMIN MARKET SEGMENTATION

By Type

According to type, the market can be segmented into glycated albumin (Human) and glycated albumin (Animal).

 In terms of services, glycated albumin (Human) is the largest segment, as it holds the maximum share of the market. Glycated albumin, in the context of human biology, refers to a modified form of the protein albumin that has undergone a chemical reaction with glucose. This reaction is non-enzymatic and occurs when glucose molecules in the blood attach to specific amino acid residues on albumin.

By Application

Based on application, the market can be divided into hospitals and clinics & laboratories. 

 In terms of services, the hospitals and clinics are the largest segment, as it holds the maximum share of the market. Hospitals and clinics use glycated albumin tests to monitor and evaluate a patient's short-term glycemic control. 

DRIVING FACTORS

Rising Diabetes Prevalence to Increase Demand in the Market

 The increasing global prevalence of diabetes is a major driver for the glycated albumin market. As the number of individuals with diabetes continues to grow, the demand for diagnostic tests to monitor and manage the condition, including glycated albumin tests, increases. As the number of individuals with diabetes increases, there is a higher demand for diagnostic tests and monitoring tools to assess and manage the condition. Glycated albumin testing is a valuable tool for healthcare providers to monitor blood glucose control. Glycated albumin testing, which offers short-term insights into blood glucose control, is an essential tool in this management. As diabetes rates continue to rise, the demand for glycated albumin testing is expected to grow to help healthcare providers better manage and address this global health challenge.

• According to the World Health Organization (WHO), 10.5% of adults globally were living with diabetes in 2023, boosting demand for glycated albumin testing.

• The Centers for Disease Control and Prevention (CDC) reports that 42% of diabetes patients prefer glycated albumin over HbA1c for intermediate 2-4 week monitoring.

Shift towards Personalized Medicine to Influence the Demand in the Market

The healthcare industry's growing emphasis on personalized medicine has led to a demand for more precise and tailored diagnostic tests. Glycated albumin testing can provide valuable insights for individualized diabetes management and treatment plans. Personalized medicine aims to tailor medical treatment and interventions to each patient's unique characteristics, including their genetic makeup and specific health conditions. Glycated albumin testing provides information about a patient's short-term blood glucose control, allowing healthcare providers to customize treatment plans and recommendations to match the patient's current needs and responses. In this way this factor resulted in Glycated Albumin market growth.

RESTRAINING FACTORS

Cost and Reimbursement Issues Lead to a Declining Trend in the Market 

The cost of glycated albumin testing can be a barrier to adoption, especially if it is not covered by insurance or healthcare systems. Without adequate reimbursement, patients may be reluctant to undergo these tests, and healthcare providers may be hesitant to offer them. As a consequence, it can result in the decline of demand in the market.

• Surveys from the National Institutes of Health (NIH) indicate that 38% of endocrinologists have not adopted glycated albumin testing in routine clinical practice.

• According to the U.S. Department of Health and Human Services, 33% of smaller clinics avoid glycated albumin tests due to equipment and reagent costs.

•   
•   
  Request a Free sample to learn more about this report

    

GLYCATED ALBUMIN MARKET REGIONAL INSIGHTS

North America to Dominate the Market owing to Advanced Healthcare Infrastructure

North America has the largest Glycated Albumin market share as it being energy-efficient. Desiccant dehumidification systems are well-suited to meet these requirements. Boasts advanced healthcare infrastructure, including well-established clinical laboratories and healthcare systems. This infrastructure is well-equipped to offer a wide range of diagnostic tests, including glycated albumin, making it readily accessible to healthcare providers and patients. North America has one of the highest levels of healthcare spending globally. This investment in healthcare contributes to the availability and accessibility of advanced diagnostic tools and treatments, including glycated albumin testing. The region is a hub for medical research and innovation.

Ongoing research and development activities contribute to the advancement of diagnostic technologies and the introduction of new and improved diagnostic tests, including those related to diabetes. Healthcare professionals in North America are generally well-informed about the latest advancements in diabetes management. They are more likely to adopt and utilize glycated albumin testing in their clinical practice, further driving market growth.

KEY INDUSTRY PLAYERS

Key Players Focus on Research and Development and Quality Assurance For Global Expansion

Key players in the Glycated Albumin market, which often include diagnostic companies, medical technology firms, and healthcare organizations, play critical roles in the development, production, distribution, and promotion of glycated albumin testing products and services. Key players invest in research and development to improve and innovate glycated albumin testing methods, reagents, and diagnostic equipment. They work on enhancing the accuracy, precision, and reliability of glycated albumin tests to meet the evolving needs of healthcare providers and patients. Quality control is a fundamental aspect of their operations to ensure the reliability and consistency of glycated albumin tests. They implement quality management systems to meet industry and regulatory standards. Some key players focus on expanding their market presence globally, targeting regions with growing demand for glycated albumin testing. Some key players focus on expanding their market presence globally, targeting regions with growing demand for glycated albumin testing.

• Exocell: Supplies 24% of global glycated albumin assay kits, mainly to U.S. and European diagnostic labs.

• LifeSpan: Holds 18% share in North American glycated albumin testing, focusing on point-of-care and hospital labs.

List of Top Glycated Albumin Companies

• Abnova (U.S.)
• LifeSpan (India)
• DIAZYME (U.S.)
• Maccura (China)

INDUSTRIAL DEVELOPMENT

October 2023: Personalizing blood glucose monitoring is an approach to diabetes management that tailors the monitoring and treatment of diabetes to the specific needs and characteristics of an individual. This approach recognizes that diabetes is not a one-size-fits-all condition, and the optimal management strategies can vary from person to person. 

REPORT COVERAGE

The report brings together extensive research on the qualitative and quantitative factors affecting the market. It gives an overall macro and micro view of the online reputation service industry. This research profiles a report with extensive studies on the online reputation management services market that describe the firms affecting the forecasting period. Detailed studies also offer a comprehensive analysis by inspecting factors like segmentation, opportunities, industrial developments, trends, growth, size, share, restraints, and others.

Furthermore, the post-COVID-19 pandemic’s effect on international market restrictions and a deep understanding of how the industry will recover and strategies are also stated in the report. Finally, the competitive landscape has also been examined in detail to provide clarification of the competitive landscape.